Community

Dr. Lucia Carvelli, Ph.D.

Our Research

In our lab we study the mechanism of action of drugs of abuse such as amphetamine and cocaine. Specifically, we investigate how these drugs alter the chemical and electrical transmission at the dopaminergic synapses. We focus our studies on the dopaminergic neurons because they are among the main types of neurons that form the reward system. Moreover, dopamine which is synthetized and stored in the dopaminergic neurons, is the major neurotransmitter released in the brain when animals are treated or self-administer drugs of abuse.

We use different model systems including neuronal cultures, heterologous expression systems and C. elegans, and a variety of techniques of molecular biology, biochemistry, pharmacology, electrophysiology, imaging, genetics and epigenetics.

Currently, we are focusing our studies on an NIH-funded project in which we investigate the epigenetic and molecular mechanisms underlying the long-term and transgenerational effects of amphetamine and cocaine.

Below you could read about our different sub areas of the lab research:

IDENTIFICATION OF NEW MOLECULAR TARGETS OF AMPHETAMINE

Despite its therapeutic importance and dangers as a recreational drug, the mechanism of action of amphetamine is still poorly understood. In vitro and in vivo studies have demonstrated that amphetamine competes for reuptake of DA and promotes reverse transport of DA through the transporter into the synapse. However, in mice lacking the DA transporter as well as the ability to synthesize DA, amphetamine still produces behavioral effects. These data suggest that mechanisms involving targets and molecules other than the DA transporter and DA itself are responsible for some of the effects generated by amphetamine. Thus, in my laboratory we searched for alternative amphetamine targets. Since the major proteins involved in dopaminergic transmission are highly conserved from worm to man, we used C. elegans as a model system to exploit the genetic tools this system offers. We found that amphetamine, besides the DA transporter, also engages the newly identified chloride channels LGC-55 to generate locomotor effects (Safratowich et al. 2013; JBC). This conclusion was supported by our behavioral data showing that whereas the single dat-1 or lgc-55 knockout animals respond to amphetamine albeit to lesser degree, the dat-1;lgc-55 double knockout animals do not respond at all to amphetamine treatments. By performing two electrodes voltage-clamped experiments in Xenopus oocytes expressing the LGC-55 channels, we demonstrated that amphetamine directly activates these channels and generates chloride-dependent currents.

Our data reveal that amphetamine activation of LGC-55 channels is within the same range of concentrations relevant in drug addiction but are orders of magnitude higher than what would be expected in an ADHD patient taking therapeutic amphetamine (5-10 µM). Indeed, amphetamine Km for LGC-55, as measured in Xenopus oocytes, is 152 µM and is consistent with the concentrations of amphetamine found in the brain of tolerant addicts (hundreds µM). Thus, if LGC-55 homologues exist in humans, our data may have an impact in the process of designing new therapies to treat addiction to amphetamine. Interestingly, a preliminary screen through the human protein data base has revealed the existence of 4 orphan proteins sharing 30-45% identity with the LGC-55 at the amino acid level. Whether these receptors are activated by amphetamine needs to be established by future studies. If one or more of these receptors are found to be activated by amphetamine, they could provide a novel therapeutic target with great promise, given the many links between aminergic signaling, mental disorder and addiction.

AMPHETAMINE ALTERS THE MECHANISM OF ACTION OF ENDOGENOUS TRACE AMINES

Phenylethylamines constitute a large class of both biogenic and synthetic compounds. Among the synthetic subgroup, amphetamine and methamphetamine are well-known for their stimulant effects. The biogenic subgroup is comprised of well-characterized neurotransmitters like dopamine, norepinephrine and serotonin, and neurotransmitters broadly named trace amines. Among the trace amine group, β-phenylethylamine (βPEA) exhibits the highest degree of chemical and structural similarities with amphetamine. In the mammalian brain, βPEA is heterogeneously distributed, with the highest levels found in the nigrostriatal and mesolimbic regions. These same areas are vastly innervated by dopaminergic neurons and are major sites of action of amphetamine. βPEA is thought to enhance dopaminergic transmission, yet its specific mechanism of action remains unclear. We are investigating whether and how βPEA affects the dopaminergic synapses. We have already demonstrated that βPEA, similarly to amphetamine, causes DA efflux through the DA transporter and activates the LGC-55 channels more efficiently than amphetamine (Safratowich et al. 2014; J Neurosci). We also found that βPEA generates stronger behavioral effects than amphetamine in C. elegans. Our in vitro and in vivo data are supported by cell specific rescue experiments which showed that, while lgc-55 knockouts do not exhibit βPEA-induced behaviors, re-expression of lgc-55cDNA in 17 classes of neurons fully restores the βPEA-induced behaviors in lgc-55 knockout animals.

The LGC-55 channels are members of the cys-loop ligand-gated ion channel (LGIC) receptors superfamily, which includes the well-studied mammalian nicotinic acetylcholine, 5HT3, glycine and GABA (type A and C) receptors. Previous data have shown that the activation of the LGIC is not simply a direct consequence of substrate binding, but rather is a multistep process where binding of the ligand induces conformation changes into the so called "flip state" from which the channel shifts into its open configuration. Full and partial agonists enable receptors to transition from the inactivated to the activated state with different efficiencies, where full agonists exhibiting a more efficient transition into the flip state. Our data show that βPEA activates the LGC-55 channels more efficiently and generates larger currents than those generated by amphetamine, suggesting that βPEA and amphetamine act as full and partial agonists for LGC-55, respectively. This phenomenon has been reported for GABAA and glycine receptors which can be potentiated by neurosteroids, benzodiazepines, anesthetics and ethanol. Similarly, our data suggest that amphetamine amplifies the transient behavioral effects induced by βPEA by potentiating the activity of the LGC-55. Considering that low amphetamine concentrations are used to treat ADHD, our observation that 1 µM amphetamine potentiates the effect of βPEA on LGC-55 channels might have important physiologic implications, if LGC-55 homologues are present in humans. The existence of amine-gated channels in mammals has long been suggested, and the fact that the human protein database shows four orphan proteins sharing 30-45% identity with LGC-55 suggest that LGC-55 homologues might indeed exist in humans. We are currently trying to clone the mammalian genes that encode for these orphan proteins.

TRANSGENERATIONAL EPIGENOMIC INHERITANCE OF ADDICTION

A more recent aspect of my research explores the epigenetic changes generated by amphetamine and the effect these changes have on gene expression, protein function and behaviors (McCowan et al. 2015; J Addiction Prevention). As previously mentioned, amphetamine is a psychostimulant and the most prescribed drug to treat ADHD. Although therapeutically used doses are generally well tolerated, amphetamine is liable to be abused by users looking for increased alertness, weight loss or athletic performance. Genome-wide analyses such as microarrays and RNA-sequencing following acute or chronic exposure to drugs of abuse have demonstrated striking changes in expression of genes that affect key regions of the brain involved in reward. These studies have suggested that the ability of drugs of abuse to alter gene expression is an important step in the initiation, maintenance and relapse to addictive behaviors. However, only a small number of studies have explored changes in gene expression caused by amphetamine, and no study has investigated the long-term effects that chronic amphetamine exposure produces. This is an important issue since both as therapeutic drug or abused psychostimulant, amphetamine is used for long periods. Thus, we asked the questions: does amphetamine cause functional/behavioral alterations in adults that were treated with amphetamine during childhood to alleviate ADHD symptoms? Does chronic amphetamine exposure cause inherited functional/behavioral changes in progeny?

My laboratory has generated data showing that amphetamine exposure of C. elegans embryos (F0 generation) causes indeed epigenetic and behavioral alterations in adult animals (manuscript in preparation). Interestingly, these alterations are transmitted to the progeny (F1-F5 generations). These data are exciting and represent the first evidence that amphetamine causes trans-generational effects. Moreover, these data offer an experimental explanation to previous social studies suggesting that addiction has an inheritable component. In fact, studies on adopted twins whose biological parents had history of addiction exhibit higher changes to become adults with addiction problems even though raised in "drug-free" environments. Our studies and results have generated high enthusiasm in the field and this project is currently funded by a NIH R01 grant.

INVESTIGATING THE EFFECTS OF ANCILLARY PROTEINS ON THE DOPAMINE TRANSPORTER

One aspect of my research is to understand the modalities of interaction between the dopamine transporter and syntaxin 1A. The dopamine transporter (DAT) is a cell membrane protein whose main function is to reuptake the dopamine released in the synaptic cleft back into the dopaminergic neurons. Previous studies suggested that the activity of DAT is regulated by allosteric proteins such as syntaxin1A (Carvelli et al. 2008 PNAS) and is altered by drugs of abuse such as amphetamine (Carvelli et al. 2010 Mol Pharmacol). Because C. elegans expresses both DAT (DAT-1) and syntaxin-1A (UNC-64), we used this model system to investigate the functional and behavioral effects caused by lack of expression of unc-64 in cultured dopaminergic neurons and in living animals. In collaboration with Dr. Elia Di Schiavi, we were able to knockdown unc-64 specifically in the dopaminergic neurons by using an inheritable RNA silencing technique. This approach leads to efficient, heritable and cell autonomous knock-downs of gene function, even in neurons usually refractory to classic RNA interference. This cell-specific knockdown method avoids the pleiotropic phenotypes caused by knockout mutations of unc-64 and ensures the transmission of dopaminergic specific unc-64 silencing to the progeny. Our data suggest that syntaxin-1A plays an important role in both functional and behavioral effects caused by amphetamine. This work was founded by an NIH R21 grant.

Dr. Lucia Carvelli
PRINCIPAL INVESTIGATOR

Dr. Lucia Carvelli

Associate Professor of Neuroscience
PhD, Pharmacology, The Mario Negri Institute for Pharmacological Research
BS, University of Calabria

Our lab seeks to understand the role of the dopaminergic system in addiction and pathological disorders such as ADHD and Parkinson's disease. Chronic exposure to drugs of abuse causes several cellular and behavioral adaptations such as tolerance, sensitization and as well as long-term effects that can be transmitted to the offspring via epigenetic mechanisms. Our main goal is to understand the mechanism of action of drugs of abuse that ultimately generate addiction.

Currently I am teaching Science of Addiction. This is a course designed as an advanced course for undergraduate students and graduate students. Using addiction as a theme, we cover basic principles of pharmacology, pharmacokinetics, biochemistry, electrophysiology and genetics. Moreover, we discuss the psychological/social aspects of addiction.

In the spirit of "mens sana in corpore sano", Latin for "a healthy mind in a healthy body", I like to exercise and cook.


Lab Members
  • Dr. Kudumala

    Dr. Sirisha Kudumala


    Amphetamine is a psychostimulant that acts on the central nervous system and increases the amount of dopamine released from the dopaminergic neurons. Chronic exposure to amphetamine may cause long lasting epigenetic changes resulting in alterations in gene expression. Many proteins in the dopaminergic pathway are conserved across species including the simple nematode C. elegans. My research focuses on understanding how amphetamine exposure during C. elegans development may lead to heritable chromatin modifications that alter the expression of specific genes in the dopaminergic system. Specifically, I use Chromatin Immuno Precipitation (ChIP) assays to shed light on chromatin modifications and transcriptional regulation occurring in response to amphetamine exposure.
  • Serena Sossi

    Serena Sossi


    Addiction seems to be highly heritable, but no obvious signs of Mendelian transmission have been found - so epigenetic mechanisms are likely to be involved. My research focuses on elucidating the mechanisms of inheritance of epigenetic changes, caused by drugs of abuse, which were previously identified in the lab. Taking advantage of C. elegans simple nervous system, conserved mechanisms, short lifespan and numerous identical progeny, I will use in vivo and in vitro approaches to help decipher the role of histone methylation and microRNAs in the inheritance of amphetamine-induced epigenetic modifications.  
Lab Publications

CONTACT US

Lucia Carvelli    |    FAU Brain Institute    |    5353 Parkside Drive, RF 104    |    Jupiter, FL33458    |    561.799.8115    |    lcarvelli@fau.edu

OUR LOCATIONS:

pins

pins
FAU Brain Institute Jupiter campus
Room 107, MC-17
5353 Parkside Drive, Jupiter, FL 33458
Phone: 561.799.8100   |   Fax: 561.799.8156
FAU Brain Institute Boca Raton campus
Room 103A, SE-43
777 Glades Road, Boca Raton, FL 33431
Phone: 561.297.4989